Case Study: Corporate Revision Myths — When Turnarounds Erase the Mess
The Pattern
Corporate history is arguably the domain most saturated with revision myths. Every successful company has an origin story. Every turnaround has a narrative. Every strategic shift has a rationale. And almost all of them are heavily sanitized.
This case study examines three corporate revision myths — not to criticize the companies involved, but to illustrate how the revision myth operates outside of science and to practice the diagnostic skills developed in this chapter.
Case A: IBM's "Strategic Transformation" (1990s)
The Clean Version
In the early 1990s, IBM faced a crisis as the computing industry shifted from mainframes to personal computers. Lou Gerstner, appointed CEO in 1993, recognized that IBM's future lay in services rather than hardware. He transformed the company from a hardware manufacturer into a technology services and consulting firm, saving the company and establishing the model for enterprise IT services that dominates today.
The Messy Version
IBM's crisis was not simply "the industry shifting." It was the result of a decade of denial about the personal computer revolution — a revolution that IBM itself had launched with the IBM PC in 1981 but then systematically mismanaged.
IBM's response to the PC era included: - The OS/2 debacle. IBM invested billions in OS/2, an operating system designed to compete with Microsoft Windows. OS/2 was technically superior in several respects but failed commercially because IBM's strategy for it was incoherent — simultaneously trying to maintain mainframe market share and compete in the PC market. - Massive layoffs. Between 1990 and 1994, IBM laid off approximately 100,000 employees — roughly 25% of its workforce. This was not "transformation." It was institutional triage. - A near-death experience. IBM lost $8 billion in 1993. The company was seriously considering breaking itself into separate units — a decision that would have ended IBM as a unified entity. - Gerstner's initial uncertainty. Gerstner, hired from RJR Nabisco (a food and tobacco company, not a technology firm), did not arrive with a services strategy. His famous early statement — "the last thing IBM needs right now is a vision" — reflected genuine uncertainty about the path forward, not strategic clarity. - The services strategy emerged gradually. The shift to services was driven partly by Gerstner's observation that IBM's customers valued integrated solutions, partly by the collapse of hardware margins that made the old business model untenable, and partly by the fact that IBM's existing global infrastructure happened to be well-suited for a services business. It was as much necessity and accident as vision.
What the Clean Version Erases
- The decade of denial about the PC revolution
- The massive human cost (100,000 jobs)
- The failed OS/2 project and billions in wasted investment
- The genuine uncertainty and desperation that preceded the "strategy"
- The role of luck and circumstance in the outcome
- The fact that Gerstner was not a technology visionary but a manager responding to crisis
The Epistemic Cost
The clean version teaches: great leaders see the future and make bold strategic choices. The messy version teaches: companies sometimes survive crises through a combination of triage, luck, abandoned wrong strategies, and the gradual emergence of a new model from the wreckage of the old one. The first lesson produces leaders who believe they need vision. The second produces leaders who understand they need humility, adaptability, and the willingness to abandon sunk costs — which is far more useful.
Case B: Netflix's "Pivot to Streaming" (2007–2013)
The Clean Version
Netflix, originally a DVD-by-mail service, recognized early that streaming would be the future of entertainment. Under Reed Hastings's leadership, the company boldly pivoted from physical media to digital streaming, eventually becoming the dominant force in entertainment and a model for digital transformation.
The Messy Version
Netflix's transition to streaming was not a clean pivot. It was a multi-year process that included one of the most publicly humiliated strategic decisions in modern business history.
- Streaming was initially a supplement, not a replacement. Netflix launched streaming in 2007 as an add-on to its DVD service, not as a replacement. The company did not "recognize early" that streaming would replace DVDs — it hedged.
- The Qwikster disaster (2011). In September 2011, Netflix announced it would split its DVD and streaming businesses into separate companies, with the DVD service renamed "Qwikster." The public response was catastrophic. Netflix lost 800,000 subscribers in a single quarter. The stock price dropped 77% from its July high. Reed Hastings was named Fortune's "Businessperson of the Year" — in mockery. Netflix reversed the Qwikster decision within weeks.
- The content licensing crisis. Netflix's early streaming library depended on licensing deals with studios. When those deals expired and studios realized streaming's potential, they pulled their content and launched competing services. Netflix's pivot to original content was driven by this existential threat, not by a pre-existing creative vision.
- International expansion was expensive and uncertain. Netflix's expansion outside the US involved years of losses and uncertain demand. The company bet enormous sums on international markets without knowing whether the model would translate.
What the Clean Version Erases
- The Qwikster debacle and the massive loss of subscribers and stock value
- The uncertainty about whether streaming would actually replace physical media
- The external pressure (studios pulling content) that forced the original content strategy
- The financial risk and multi-year losses of international expansion
- The role of broadband infrastructure improvements (outside Netflix's control) in making streaming viable
Case C: The Pharmaceutical "Innovation" Narrative
The Clean Version
The pharmaceutical industry drives medical progress through an innovation pipeline that moves from basic research through clinical trials to approved therapies. The high cost of drug development (often cited as $1-2 billion per approved drug) reflects the enormous investment required to bring safe, effective treatments to patients.
The Messy Version
The pharmaceutical industry's history includes: - Thalidomide (1957–1962). Marketed as a safe sedative for pregnant women, thalidomide caused severe birth defects in thousands of children worldwide. The disaster led to fundamental changes in drug regulation — but only after catastrophic harm. - Vioxx (1999–2004). Merck's arthritis drug was withdrawn after evidence emerged that it increased the risk of heart attacks and strokes. Internal documents later revealed that Merck had been aware of cardiovascular risks before the drug was withdrawn. Estimates suggest that Vioxx may have caused tens of thousands of heart attacks. - The opioid crisis (1990s–present). Pharmaceutical companies, particularly Purdue Pharma, aggressively marketed opioid painkillers with misleading claims about their addictive potential. The resulting epidemic has killed hundreds of thousands of Americans. - Me-too drugs and incremental innovation. A substantial portion of pharmaceutical R&D is devoted to developing drugs that are marginally different from existing therapies — enough to justify new patents and pricing, but not enough to represent genuine therapeutic innovation. - Publicly funded research. Many breakthrough drugs were developed using research funded by the National Institutes of Health or other public agencies. The pharmaceutical industry's "innovation" often begins with publicly funded discovery, to which the industry adds development and commercialization — a legitimate contribution, but not the same as "driving medical progress."
What the Clean Version Erases
The pharmaceutical revision myth erases the disasters (thalidomide, Vioxx, opioids) or presents them as isolated incidents rather than structural features of an incentive system that rewards speed-to-market over safety. It erases the role of public funding in basic research. It erases the predominance of incremental innovation. And it presents the high cost of drug development as evidence of industry investment rather than as a figure that includes the cost of marketing, failed me-too drugs, and regulatory compliance that the industry itself sometimes resists.
Analysis Questions
1. For each of the three cases (IBM, Netflix, the pharmaceutical industry), identify which mechanisms of revision from section 20.3 are most active: compression, hindsight inevitability, institutional self-interest, survivor narration, the "we always knew" claim, or the hero narrative.
2. Corporate revision myths are often more deliberate than scientific ones — companies have PR departments, marketing teams, and strategic communication functions. Does this make them more or less dangerous than scientific revision myths? Argue both sides.
3. The chapter argues that revision myths are harmful because they make current errors invisible. Apply this to the pharmaceutical narrative: how does the "innovation pipeline" revision myth affect the public's ability to evaluate current pharmaceutical industry practices?
4. Choose a company or industry you know well and write both the clean and messy versions of a significant event in its history (a turnaround, a crisis, a strategic shift). Then identify what the clean version erases and what epistemic cost that erasure carries.
5. Is there a version of corporate history that would be both honest about the messiness and useful for teaching business strategy? Design the structure of a "messy case study" that includes the sanitized elements (strategic decisions, outcomes) alongside the unsanitized ones (denial, failure, luck, human cost). What would this teach that the clean version doesn't?
Key Takeaway
Corporate revision myths are not just flattering — they are instructive in the wrong way. They teach that success comes from vision, leadership, and bold strategy. The messy versions teach that success often comes from surviving crises, abandoning wrong strategies, responding to external pressures, and benefiting from circumstances outside the organization's control. The second set of lessons is less inspiring but far more useful for anyone who actually needs to navigate institutional change.